contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


revenio-group-new-long-term-opportunities-created

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Analytiker

Juha Kinnunen

Revenio är verksamt inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar såsom glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.

Q3-resultatet var lägre än förväntat på grund av valutakurseffekter och ökad kostnadsstruktur, men förvärvet av Thirona Retina förbättrar långsiktiga tillväxtmöjligheter. Värderingen (2025e EV/EBIT 21x) är attraktiv om bolaget kan upprätthålla vinsttillväxten. Intäktsökningen i Q3 var 15 % justerat för valutakursförändringar, med tillväxt i försäljningen av tonometrar och tvåsiffrig tillväxt inom bildbehandlingsutrustning. Revenios prognos för 2024 förblir oförändrad, och bolaget förväntar sig en intäktsökning på 5–10 % justerat för valutakursvariationer. Små negativa faktorer för framtida potential inkluderar avsaknaden av en separat ersättningskod i USA för HOME2-enheten samt en möjlig FDA-fördröjning för AI-partnern. Thirona bidrar också till ökade kostnader, vilket har minskat vinstprognoserna för 2025 med cirka 5 %. Med förväntad vinsttillväxt förblir värderingen attraktiv, och bolagets långsiktiga potential förblir stark.                    Inderes              Revenio Q3'24: Slight increase in cost structure - Inderes    Q3 results were below our expectations, but the main reason for the disappointment was negative FX effects. However, our forecasts for the next few years have been lowered slightly as the company's cost structure has slightly ballooned, but we...

Revenio publicerar sitt Q3-resultat på torsdag. Förväntningarna är god omsättningstillväxt och en betydande resultatförbättring efter en svag jämförelseperiod. Lönsamheten påverkas av löneinflation och kostnader relaterade till FDA-ansökan. Kvartalets höjdpunkter var förvärvet av Thirona Retina och lanseringen av tonometern iCare ST500, som står i centrum för framtida tillväxtutsikter.                    Inderes              Revenio Q3'24 preview: Interesting quarter behind - Inderes    Revenio will announce its Q3 results on Thursday at about 9.00 am EET. We expect the company to deliver good revenue growth and a significant improvement in earnings, helped by a very weak Q3'23 by the company's standards.

Detta är ett mycket intressant nytt koncept… och nu är det dags för ett mycket intressant företag, nämligen Revenio.                    Inderes              Value Creators: Revenio - Inderes    In the Value Creators concept, we highlight companies that have created substantial shareholder value. In this report, we introduce Revenio - a global leader in ophthalmic equipment and software solutions, with a focus on eye care solutions.

Revenios dotterbolag Icare lanserade igår tonometern iCare ST500, som kombinerar de viktigaste funktionerna i iCare-teknologin för ögontrycksmätning med en modern design baserad på spaltlampa. Enhetens teknologi motsvarar modellen IC200, men dess användning och design skiljer sig avsevärt. Lanseringen stöder företagets strategi och ökar marknadsandelen.                    Inderes              Revenio’s Icare launched slit lamp tonometer - Inderes    Revenio's subsidiary Icare yesterday announced the launch of the iCare ST500 packing the essential features of iCare rebound tonometry technology into a modern slit lamp-based design.

Juha, Juha Kinnunen, the man who don’t know fear Juha has once again provided us with an excellent analysis of this highly interesting company. We reiterate our Accumulate recommendation for Revenio and raise our target price to EUR 32.0 (was EUR 28.0). The company’s revenue growth accelerated faster than we anticipated, and the Q2 operating result exceeded our expectations. The company has returned to profit growth as expected, and future growth drivers are developing promisingly, laying the foundation for profitable growth in the medium term as well. The share’s valuation (2025e, adj. EV/EBIT 20x) is no longer cheap, but we believe it is justified and the upside from the 2025 earnings growth gives a reason to stay on board.                   Inderes              Revenio Q2'24: Company progress on track - Inderes    Revenio's revenue growth accelerated faster than we anticipated, and the Q2 operating result exceeded our expectations. The company has returned to profit growth as expected, and future growth drivers are developing promisingly, laying the foundation...

Revenio has brought a lot of joy to Finnish investors, and a bit to foreign ones as well. Its stock has risen significantly over the years, although it has been a bit calmer lately. Below are the analyst’s comments, as the company will soon publish its Q2 report.                   Inderes              Revenio Q2'24 preview: Back to earnings growth - Inderes    Revenio will announce its Q2 results next week on Thursday at about 9.00 am EEST. We expect Revenio's revenue and result to return to a clear upward trend, helped by the company's exceptionally weak Q2'23 comparison period. Together with revenue,...

Better late than never! I’ll try to be active now and compensate historical lapses

Revenio Group

Revenio's Q1 report was very strong, especially in terms of profitability, and the long-term story continues to progress convincingly. On Wednesday, the company told about an interesting opportunity...

<p>Revenio's Q1 report was very strong, especially in terms of profitability, and the long-term story continues to progress convincingly. On Wednesday, the company told about an interesting opportunity in AI, which opens new growth opportunities for the company. However, our estimates for the next few years remain largely unchanged and the share valuation (2023e P/E 55x and EV/EBIT 43x) is very high. In the long term, the expected very strong earnings growth will correct even the higher valuation multiples, but due to the strong headwind of growth companies’ pricing, we still see risks in the valuation and refrain from further purchases. </p> 

	2021	22e	23e
Omsättning	78,8	95,7	115,9
tillväxt-%	29,07 %	21,49 %	21,03 %
EBIT (adj.)	24,5	29,1	37,2
EBIT-%	31,13 %	30,39 %	32,13 %
EPS (adj.)	0,74	0,87	1,08
Utdelning	0,34	0,46	0,57
Direktavkastning	0,61 %	1,68 %	2,09 %
P/E (just.)	75,13	31,10	25,18
EV/EBITDA	57,67	23,06	17,98

Revenio Group: New long-term opportunities created

Revenio Group

Key Estimate Figures2022-04-29

Revenio Group

Key Estimate Figures2022-04-29

Beställ vårt nyhetsbrev — inget användarkonto krävs!